serum calprotectin
Diagnostic and Prognostic Value of Serum Calprotectin in Septic Shock Patients
7
Serum calprotectin levels as a marker of disease activity in children with juvenile idiopathic arthritis
109
Serum Calprotectin and Prealbumin Levels among Ovarian Cancer Patients Aged 30 45 Years
10
Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti TNF treatment in patients with rheumatoid arthritis
7
Original Article Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein
6
Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis
6
Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non radiographic axial spondyloarthritis
12
<p>Serum Calprotectin, a Marker of Neutrophil Activation, and Other Mediators of Inflammation in Response to Various Types of Extreme Physical Exertion in Healthy Volunteers</p>
9
Serum Calprotectin Level for Diagnosis and detection of Disease Activity in Rheumatoid Arthritis
5
A new turbidimetric immunoassay for serum calprotectin for fully automatized clinical analysers
8
Calprotectin in Cystic Fibrosis
7
Download Download PDF
6
Calprotectin as a Biomarker for Melioidosis Disease Progression and Management
6
Assessment of Calprotectin as a Serodiagnostic Marker for Neonatal Sepsis
10
Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
6
Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1 year prospective cohort study
11
Leptin, ghrelin and calprotectin: inflammatory markers in childhood asthma?
6
Proinflammatory S100 proteins as clinical markers of juvenile idiopathic arthritis
9
Calprotectin (S100A8/9) as serum biomarker for clinical response in proof of concept trials in axial and peripheral spondyloarthritis
9
Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin : a ‘real world’ view
8